JPRN-UMIN000039016招募中未知
IRD (ixazomib, lenalidomide, and dexamethasone) consolidation therapy after autologous peripheral hematopoietic stem cell transplantation for elderly multiple myeloma patients. - IRD consolidation after ASCT
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Peripheral neuropathy grade > 2 2) Uncontrolled diabetes. 3) Uncontrolled hypertension, arrhythmia, or heart failure. 4) Uncontrolled infectious diseases. 5) Uncontrolled psychiatric disorders. 6) Pregnant or lactating patients. 7) Allergic to ixazomib or lenalidomide. 8) Inability to comply with RevMmate. 9) Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
研究者
相似试验
进行中（未招募）
1 期
Pomalidomide, ixazomib, and dexamethasone (PId) with or without intensification by cyclophosphamide (PICd): A phase II study in relapsed or refractory multiple myelomaRelapsed/refractory multiple myelomaMedDRA version: 21.1Level: LLTClassification code 10067095Term: Multiple myeloma progressionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001757-16-DEGWT-TUD GmbH60
进行中（未招募）
1 期
Evaluation of Ixazomib, Lenalidomide, Dexamethasone in Newly Diagnosed Multiple Myeloma Patients eligible for High Dose TherapyEUCTR2014-003467-37-FRCHU de Toulouse46
进行中（未招募）
1 期
Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trialMultiple MyelomaEUCTR2013-003266-14-NOHOVON Foundation142
进行中（未招募）
1 期
Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trialMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2013-003266-14-SEHOVON Foundation142
招募中
不适用
Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trial.Multipel Myeloom, Ixazomib, elderly patientsNL-OMON29252Stichting HOVO142